Efficacy of belimumab in Primary Sjögren's syndrome: A systematic review
Tài liệu tham khảo
Rischmueller, 2016, Primary Sjögren's syndrome, Best Pract Res Clin Rheumatol, 30, 189, 10.1016/j.berh.2016.04.003
Qin, 2015, Epidemiology of primary Sjogren's syndrome: a systematic review and meta-analysis, Ann Rheum Dis, 74, 1983, 10.1136/annrheumdis-2014-205375
Kassan, 2004, Clinical manifestations and early diagnosis of Sjögren syndrome, Arch Intern Med, 164, 1275, 10.1001/archinte.164.12.1275
Brito-Zerón, 2017, Characterization and risk estimate of cancer in patients with primary Sjögren syndrome, J Hematol Oncol, 10, 90, 10.1186/s13045-017-0464-5
Schneider, 1999, BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth, J Exp Med, 189, 1747, 10.1084/jem.189.11.1747
Mariette, 2003, The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome, Ann Rheum Dis, 62, 168, 10.1136/ard.62.2.168
Ittah, 2006, B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren's syndrome, Arthritis Res Therapy, 8, R51, 10.1186/ar1912
Quartuccio, 2013, BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands, Rheumatology (Oxford, England), 52, 276, 10.1093/rheumatology/kes180
Navarra, 2011, Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial, Lancet, 377, 721, 10.1016/S0140-6736(10)61354-2
Sackett, 1996, Evidence based medicine: what it is and what it isn’t, BMJ, 312, 71, 10.1136/bmj.312.7023.71
Liberati, 2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration, PLoS Med., 6, e1000100, 10.1371/journal.pmed.1000100
Harbour, 2001, A new system for grading recommendations in evidence based guidelines, BMJ, 323, 334, 10.1136/bmj.323.7308.334
Mariette, 2015, Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study, Ann Rheum Dis, 74, 526, 10.1136/annrheumdis-2013-203991
De Vita, 2015, Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study, Rheumatology, 54, 2249
Quartuccio, 2016, Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjogren's syndrome: follow-up after the end of the phase II open-label BELISS study, Clin Exp Rheumatol, 34, 311
Souza, 2016, Rituximab effectiveness and safety for treating primary Sjogren's syndrome (pSS): systematic review and meta-analysis, PLOS ONE, 11, e0150749, 10.1371/journal.pone.0150749
Brito-Zeron, 2017, Characterization and risk estimate of cancer in patients with primary Sjogren syndrome, J Hematol Oncol, 10, 90, 10.1186/s13045-017-0464-5
Nocturne, 2016, Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sjogren's syndrome, Arthritis Rheumatol (Hoboken, NJ), 68, 977, 10.1002/art.39518
Fragkioudaki, 2016, Predicting the risk for lymphoma development in Sjogren syndrome: an easy tool for clinical use, Medicine, 95, e3766, 10.1097/MD.0000000000003766
Furie, 2018, Long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus: a continuation of the Phase 3 United States BLISS-76 trial, Arthritis Rheumatol (Hoboken, NJ), 10.1002/art.40439